David Walk, MD, FAAN

My clinical and research interests include motor neuron disorders, Charcot-Marie-Tooth (CMT), and other neuropathies

• MDA Dr. Stephen Smith Champion of Hope Award, 2018
• Minneapolis-St. Paul Magazine Top Doctor, 2010, 2012-2020

2021-present PharNEXT
PXT3006
Local Principal Investigator

2020-present ALS Platform Trial
Healy Center for ALS
Local Principal Investigator

2021-present MediciNova
COMBAT-ALS
Co-Investigator

2021-presen Apellis
APL-ALS-206
Co-Investigator

2021-present PHARNext
Phase III Trial of PXT3006 in CMT1A
Local Principal Investigator

2021-present Spastic Paraplegia Foundation
PLS Natural History Study
Local Principal Investigator

2016-present  NIH Advancing Treatment for Pancreatitis: A Prospective Observational Study of TPIAT Co-Investigator

2016-present PHARNext
Phase III Trial of PXT3003 in CMT1A and Open-Label Extension
Local Principal Investigator

2016-present Inherited Neuropathy Consortium Rare Disease Clinical Research Network Genetics of CMT - Modifiers of CMT1A, New Causes of CMT
Local Principal Investigator

2016-present Inherited Neuropathy Consortium Rare Disease Clinical Research Network A Natural History Study of CMT1B, CMT2A, CMT4A and CMT4C
Local Principal Investigator

1. Walk D, editor. Handbook of Neuromuscular Medicine. New York, Springer; 2018.
2. Miller RG, Zhang R, Bracci PM, Azhir A, Barohn R, Bedlack R, Benatar M, Berry JD, Cudkowicz M, Kasarskis EJ, Mitsumoto H, Walk D, Shefner J, McGrath MS. Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: pre-specified and post-hoc analyses. Muscle Nerve 2022; in press.
3. Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME; Healey ALS Platform Trial Study Group. Adaptive platform trials to transform Amyotrophic Lateral Sclerosis therapy development. Ann Neurol 2022;91:165-175.
4. Raabe W, Walk D. Median amplitude and frequency analysis of sensory nerve responses to intraepidermal stimulation. J Neurosci Meth 2022.
5. Granit V, Grignon AL, Wuu J, Katz J, Walk D, Hussain S, Hernandez J, Jackson C, Caress J, Yosick T, Smider N, Benatar M. Harnessing the power of the electronic health record for ALS research and quality improvement: CReATe CAPTURE-ALS and the ALS toolkit. Muscle Nerve 2022;65:154-161.
6. Attarian S, Young P, Brannagan TH, Adams D, Van Damme P, Thomas FP, Casanovas C, Tard C, Walter MC, Péréon Y, Walk D, Stino A, de Visser M, Verhamme C, Amato A, Carter G, Magy L, Statland JM, Felice K. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis 2021;16:433.
7. Placek K, Benatar M, Wuu J, Rampersaud E, Hennesy L, et al. Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Mol Med 2021;13:e12595.
8. Barohn RJ, Gajewski B, Pasnoor M, Brown A, Herbelin LL, et al. Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparison effectiveness randomized trial. JAMA Neurol 2021;78:68-76.
9. Mitsumoto H, Turner MR; all Delegates of the PLS Conference. Preface: promoting research in PLS: current knowledge and future challenges. Amyotroph lateral scler frontotemporal degener 2020; suppl 1:1-2.
10. Pipis M, Feely SME, Polke JM, Skorupinska M, Perez L, et al. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain 2020;143:3580-3602.
11. Raabe W, Walk D. Slowly conducting potentials in human sensory nerves. J Neurosci Methods 2020;351.
12. Pipis M, Feeley SME, Polky JM, Skorupinska M, et al. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain 2020;143:3589-3602.
13. Senderek J, Lassuthova P, Kabzinska D, Abreu L, et al. The genetic landscape of axonal neuropathies in the middle-aged and elderly: focus on MME. Neurology 2020;95:e3163-e3179.
14. Bis-Brewer DM, Gan-Or Z, Sleiman P, Hakonarson H, Fazal S, and the Inherited Neuropathy Consortium. Assessing non-Mendelian inheritance in inherited axonopathies. Genet Med 2020;22:2114-2119.
15. Pisharady P, Eberly LE, Cheong I, Manousakis G, Guliani G, Clark HB, Bathe M, Walk D, Lenglet C. Tract-specific longitudinal study of cervical cord diffusion MRI in Amyotrophic Lateral Sclerosis. Commun Biol 2020;3:370
16. Cortese A, Zhu Y, Rebolo a, Negri S, Courel S, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Gen, 2020;52:473-481.
17. Turner MR, Barohn RJ, Corcia P, Fink JK, Harms MB, Kiernan MC, Ravits J, Silani V, Simmons Z, Statland J, van den Berg LH; Delegates of the 2nd International PLS Conference, Mitsumoto H. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry 2020;
    91:373-377.
18. Muley SA, Jacobsen B, Parry G, Usman U, Ortega E, Walk D, Allen J, Pasnoor M, Varon M, Dimachkie MM. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2020;61:575-579.
19. Wasan AD, Alter BJ, Edwards RR, Argoff CE, Sehgal N, Walk D, Moeller-Bertram T, Wallace MS, Backonja M. Test-retest and inter-examiner reliability of a novel bedside quantitative sensory testing battery in postherpetic neuralgia patients. J Pain 2020;7-8:858-868.
20. Mitsumoto H, Chiuzan C, Gilmore M, Zhang Y, Simmons Z, et al. Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale. Muscle Nerve 2020;61:163-172.
21. Fridman V, Sillau S, Acsadi G, Bacon C, Bray K, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology 2020;94:e884-e896.
22. Barney C, Merbler A, Simone F, Walk D, Symons FJ. Investigating the feasibility of a modified quantitative sensory testing approach to profile sensory function and predict pain outcomes following intrathecal baclofen implant surgery in cerebral palsy. Pain Medicine, 2020;21:109-117.
23. Walk D. Neurophysiologic techniques to investigate small fiber excitability. Muscle & Nerve 2019;60:345-346.
24. Cheong I, Deelchand D, Eberly L, Marjanska M, Manousakis G, Guliani G, Walk D, Oz G. Neurochemical correlates of functional decline in amyotrophic lateral sclerosis. J Neurol Neursurg Psychiatr; 2019;90:294-301.
25. Walk, D. Measures of cutaneous pain perception and nociceptor density: more than skin deep. Muscle & Nerve 58;2018;58:472-474.
26. Salter CG, Beijer D, Hardy H, Barwick K, Bower M, Mademan I, De Jonghe P, Deconinck T, Russell MA, McEntagart MM, Chioza B, Blakely RD, Chilton JK, De Bleecker J, Baets J, Baple EL, Walk D, Crosby AH. Truncating SLC5A7 mutations underlie a spectrum of dominant hereditary motor neuropathies. Neurology Genetics 2018;4:e222.
27. Panosyan FB, Laura M, Rossor AM, Pisciotta C, Piscosquito G, Burns J, and the Inherited Neuropathies Consortium. Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1). Neurology 2017;89:927-935.
28. Cheong I, Marjanska M, Deechand D, Eberly L, Walk D, Oz G. Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis. Neurochem Res, 2017;42:1833-1844.
29. Walk D. Using random forest methods to identify factors associated with diabetic neuropathy: a novel approach. Pain Med 2017;18:1-2.
30. Walk D, Poliak-Tunis M. Chronic pain management: An overview of taxonomy, conditions commonly encountered, and assessment. Med Clin 2016;100:1-16.
31. Macchi Z, Wang, Y, Moore D, Katz J; Saperstein D, Walk D, et al. Possible Mitochondrial Target Engagement in an Open Label Trial of Rasagiline for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:345-352.